Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
Authors
Keywords
-
Journal
Clinical Research in Cardiology
Volume 111, Issue 5, Pages 548-559
Publisher
Springer Science and Business Media LLC
Online
2022-03-16
DOI
10.1007/s00392-021-01957-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative effectiveness of oral anticoagulants in everyday practice
- (2021) A John Camm et al. HEART
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation
- (2019) David J. Graham et al. AMERICAN JOURNAL OF MEDICINE
- Evaluating the Use of Nonrandomized Real World Data Analyses for Regulatory Decision Making
- (2019) Jessica M. Franklin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program
- (2019) Michał Mazurek et al. AMERICAN HEART JOURNAL
- Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
- (2018) Larry R. Jackson et al. Journal of the American Heart Association
- Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation
- (2017) George Ntaios et al. STROKE
- Stroke prevention in atrial fibrillation: Past, present and future
- (2017) Ben Freedman et al. THROMBOSIS AND HAEMOSTASIS
- A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system
- (2015) Janet Schnee et al. THROMBOSIS AND HAEMOSTASIS
- Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation
- (2014) Torben Bjerregaard Larsen et al. AMERICAN JOURNAL OF MEDICINE
- Additional Events in the RE-LY Trial
- (2014) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
- (2013) Menno V. Huisman et al. AMERICAN HEART JOURNAL
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
- (2012) Stefan H. Hohnloser et al. CIRCULATION
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started